Stocktwits on MSN
Exicure stock soars 40% after stem cell drug helps most patients hit phase 2 goal — traders call it 'cheap' at current levels
Phase 2 data showed rapid increases in CD34+ stem cells, allowing same-day dosing and collection. ・Daratumumab-treated ...
Exicure, a clinical-stage biotechnology company specializing in next-generation stem-cell mobilization therapies, has staged ...
Exicure shares trade higher after Phase 2 data show nearly 90% of patients reached key cell collection targets using its ...
Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR) a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced that, as of July 1, 2025, the Company ...
Hosted on MSN
Exicure Redeems Convertible Bonds for Liquidity
Exicure ( (XCUR)) just unveiled an announcement. On November 10, 2025, Exicure, Inc. redeemed in full the 4.5 billion KRW, approximately $3.125 million USD, of 2.90% Convertible Bonds due 2028, ...
Exicure’s investigational small molecule succeeded in mobilizing key blood-forming cells in almost 90% of patients in a phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback